Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 15/20 | 0.60 |
| ▸ | ACACA | Q13085 | 13/20 | 0.60 |
| ▸ | F2RL3 | Q96RI0 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968429 | 0.92 | ACACB (0.61) | ACACBACACAF2RL3 | |
| SCHEMBL9113117 | 0.92 | ACACB (0.61) | ACACBACACAF2RL3 | |
| SCHEMBL9112584 | 0.92 | ACACB (0.70) | ACACBACACAF2RL3 | |
| SCHEMBL15968642 | 0.92 | ACACB (0.70) | ACACBACACAF2RL3 | |
| SCHEMBL9114222 | 0.91 | ACACB (0.60) | ACACBACACAF2RL3 | |
| SCHEMBL9113883 | 0.90 | ACACB (0.59) | ACACBACACAF2RL3 | |
| SCHEMBL9909867 | 0.88 | ACACB (0.49) | ACACBACACAF2RL3 | |
| SCHEMBL9112039 | 0.86 | ACACB (0.56) | ACACBACACAF2RL3 | |
| SCHEMBL9111840 | 0.86 | ACACB (0.64) | ACACBACACA | |
| SCHEMBL9114834 | 0.84 | ACACB (0.60) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649062-B1 | BICYCLIC COMPOUNDS AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | TAKEDA PHARMACEUTICAL (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8729102-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| US-8729102-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| WO-2012074126-A9 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-06 | — | — | WO | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2012074126-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142714-A1 | BICYCLIC COMPOUND | ACACA, ACACB, FABP4 | ACACB 2/4885ACACA 1/4885F2RL3 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.